Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Clinical significance of gelsolin-like actin-capping protein expression in oral carcinogenesis: an immunohistochemical study of premalignant and malignant lesions of the oral cavity

Authors: Hitomi Nomura, Katsuhiro Uzawa, Takashi Ishigami, Yukinao Kouzu, Hirofumi Koike, Katsunori Ogawara, Masashi Siiba, Hiroki Bukawa, Hidetaka Yokoe, Hitoshi Kubosawa, Hideki Tanzawa

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Gelsolin-like actin-capping protein (CapG) is a ubiquitous gelsolin-family actin-modulating protein involved in cell signalling, receptor-mediated membrane ruffling, phagocytosis, and motility. CapG has generated great interest due to its oncogenic function in the control of cell migration or invasion in a variety of cancer cells. We previously applied proteomic methods to characterize differentially expressed proteins in oral squamous-cell carcinoma (OSCC) cells and detected significantly high expression levels of CapG in OSCC-derived cell lines compared to human normal oral keratinocytes. In the current study, to further determine the potential involvement of CapG in OSCC, we evaluated the status of CapG protein and mRNA expression in human oral premalignant lesions (OPLs) and primary OSCCs and correlated the results with clinicopathologic variables.

Methods

Matched normal and tumour tissue sections of 79 human primary OSCCs and 28 OPLs were analyzed for CapG expression by immunohistochemistry (IHC). Correlations between CapG-immunohistochemical staining scores of OSCCs and clinicopathologic features were evaluated by Fisher's exact test. Real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to estimate CapG expression at the mRNA level.

Results

In IHC, substantial up-regulation of CapG protein was observed in primary OSCCs (52%) and OPLs (64%), whereas corresponding normal tissues showed consistently weak or absent immunoreactivity of CapG. qRT-PCR data were consistent with the protein expression status. Moreover, CapG expression was correlated with the TNM stage grading of OSCCs.

Conclusion

Our finding of frequent dysregulated expression of CapG in premalignant and malignant lesions together with an association with an advanced clinical disease stage suggests that CapG could contribute to cancer development and progression and that CapG may have potential as a biomarker and a therapeutic target for OSCC.
Appendix
Available only for authorised users
Literature
1.
Sudbo J, Reith A: The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. Int J Cancer. 2005, 115: 339-345. 10.1002/ijc.20896.CrossRefPubMed
2.
Lippman SM, Sudbo J, Hong WK: Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol. 2005, 23: 346-356. 10.1200/JCO.2005.09.128.CrossRefPubMed
3.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.CrossRefPubMed
4.
La Vecchia C, Lucchini F, Negri E, Levi F: Trends in oral cancer mortality in Europe. Oral Oncol. 2004, 40: 433-439. 10.1016/j.oraloncology.2003.09.013.CrossRefPubMed
5.
Chuthapisith S, Layfield R, Kerr ID, Eremin O: Principles of proteomics and its applications in cancer. Surgeon. 2007, 5: 14-22.CrossRefPubMed
6.
7.
Koike H, Uzawa K, Nakashima D, Shimada K, Kato Y, Higo M, Kouzu Y, Endo Y, Kasamatsu A, Tanzawa H: Identification of differentially expressed proteins in oral squamous cell carcinoma using a global proteomic approach. Int J Oncol. 2005, 27: 59-67.PubMed
8.
Nakashima D, Uzawa K, Kasamatsu A, Koike H, Endo Y, Saito K, Hashitani S, Numata T, Urade M, Tanzawa H: Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. Int J Cancer. 2006, 118: 704-713. 10.1002/ijc.21318.CrossRefPubMed
9.
Kasamatsu A, Uzawa K, Nakashima D, Kouzu Y, Endo Y, Koike H, Yokoe H, Harada K, Sato M, Tanzawa H: A proteomics approach to characterizing human submandibular gland cell lines by fluorescent two-dimensional differential in-gel electrophoresis. Int J Mol Med. 2006, 17: 253-260.PubMed
10.
Kato H, Uzawa K, Onda T, Kato Y, Saito K, Nakashima D, Ogawara K, Bukawa H, Yokoe H, Tanzawa H: Down-regulation of 1D-myo-inositol 1,4,5-trisphosphate 3-kinase A protein expression in oral squamous cell carcinoma. Int J Oncol. 2006, 28: 873-881.PubMed
11.
Yu FX, Johnston PA, Sudhof TC, Yin HL: gCap39, a calcium ion- and polyphosphoinositide-regulated actin capping protein. Science. 1990, 250: 1413-1415. 10.1126/science.2255912.CrossRefPubMed
12.
Prendergast GC, Ziff EB: Mbh 1: a novel gelsolin/severin-related protein which binds actin in vitro and exhibits nuclear localization in vivo. EMBO J. 1991, 10: 757-766.PubMedPubMedCentral
13.
Dabiri GA, Young CL, Rosenbloom J, Southwick FS: Molecular cloning of human macrophage capping protein cDNA. A unique member of the gelsolin/villin family expressed primarily in macrophages. J Biol Chem. 1992, 267: 16545-16552.PubMed
14.
Pollard TD, Borisy GG: Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003, 112: 453-465. 10.1016/S0092-8674(03)00120-X.CrossRefPubMed
15.
Welch MD, Mullins RD: Cellular control of actin nucleation. Annu Rev Cell Dev Biol. 2002, 18: 247-288. 10.1146/annurev.cellbio.18.040202.112133.CrossRefPubMed
16.
Janmey PA: The cytoskeleton and cell signaling: component localization and mechanical coupling. Physiol Rev. 1998, 73 (3): 763-781.
17.
Maruta H, He H, Tikoo A, Vuong T, Nur-E-Kamal M: G proteins, phosphoinositides, and actin-cytoskeleton in the control of cancer growth. Microsc Res Tech. 1999, 47: 61-66. 10.1002/(SICI)1097-0029(19991001)47:1<61::AID-JEMT6>3.0.CO;2-Y.CrossRefPubMed
18.
Janmey Paul: Medical aspects of the actin cytoskeleton. Curr Opin Cell Biol. 1995, 7: 111-117. 10.1016/0955-0674(95)80052-2.CrossRefPubMed
19.
Rao J, Li N: Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets. 2004, 4: 345-354. 10.2174/1568009043332998.CrossRefPubMed
20.
21.
Johnston PA, Yu FX, Reynolds GA, Yin HL, Moomaw CR, Slaughter CA, Südhof TC: Purification and expression of gCap39. An intracellular and secreted Ca2(+)-dependent actin-binding protein enriched in mononuclear phagocytes. J Biol Chem. 1990, 265: 17946-17952.PubMed
22.
Kassis J, Lauffenburger DA, Turner T, Wells A: Tumor invasion as dysregulated cell motility. Semin Cancer Biol. 2001, 11: 105-117. 10.1006/scbi.2000.0362.CrossRefPubMed
23.
Yamazaki D, Kurisu S, Takenawa T: Regulation of cancer cell motility through actin reorganization. Cancer Sci. 2005, 96: 379-386. 10.1111/j.1349-7006.2005.00062.x.CrossRefPubMed
24.
Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, Maruyama T, Asamura H, Matsuno Y, Onizuka M, Murakami Y: Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res. 2005, 11: 2954-2961. 10.1158/1078-0432.CCR-04-2206.CrossRefPubMed
25.
Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, Tubbs RR, Adams JC, Hicks DG: The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res. 2005, 11: 186-192.PubMed
26.
Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, Ino Y, Ono M, Hirohashi S: Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology. 2005, 128: 51-62. 10.1053/j.gastro.2004.10.004.CrossRefPubMed
27.
Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J: A novel role of myosin VI in human prostate cancer. Am J Pathol. 2006, 169: 1843-1854. 10.2353/ajpath.2006.060316.CrossRefPubMedPubMedCentral
28.
Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, Taniguchi S: Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res. 2004, 10: 572-580. 10.1158/1078-0432.CCR-1323-03.CrossRefPubMed
29.
Sun HQ, Yamamoto M, Mejillano M, Yin HL: Gelsolin, a multifunctional actin regulatory protein. J Biol Chem. 1999, 274: 33179-33182. 10.1074/jbc.274.47.33179.CrossRefPubMed
30.
Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL, Hayoz D: Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci. 2004, 61: 2614-2623. 10.1007/s00018-004-4225-6.CrossRefPubMed
31.
McGough AM, Staiger CJ, Min JK, Simonetti KD: The gelsolin family of actin regulatory proteins: modular structures, versatile functions. FEBS Lett. 2003, 552: 75-81. 10.1016/S0014-5793(03)00932-3.CrossRefPubMed
32.
Yang J, Ramnath N, Moysich KB, Asch HL, Swede H, Alrawi SJ, Huberman J, Geradts J, Brooks JS, Tan D: Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer. 2006, 6: 203-10.1186/1471-2407-6-203.CrossRefPubMedPubMedCentral
33.
Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB: Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat. 2001, 65: 11-21. 10.1023/A:1006446108411.CrossRefPubMed
34.
Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, Dietel M, Wiechen K: Loss of gelsolin expression in human ovarian carcinomas. Eur J Cancer. 2005, 41: 461-469. 10.1016/j.ejca.2004.10.025.CrossRefPubMed
35.
Shieh DB, Chen IW, Wei TY, Shao CY, Chang HJ, Chung CH, Wong TY, Jin YT: Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications. Oral Oncol. 2006, 42: 599-606. 10.1016/j.oraloncology.2005.10.021.CrossRefPubMed
36.
Pellieux C, Desgeorges A, Pigeon CH, Chambaz C, Yin H, Hayoz D, Silacci P: CapG, a gelsolin family protein modulating protective effects of unidirectional shear stress. J Biol Chem. 2003, 278 (31): 29136-29144. 10.1074/jbc.M300598200. Epub 2003 May 17.CrossRefPubMed
37.
Sun HQ, Kwiatkowska K, Wooten DC, Yin HL: Effects of CapG overexpression on agonist-induced motility and second messenger generation. J Cell Biol. 1995, 129 (1): 147-156. 10.1083/jcb.129.1.147.CrossRefPubMed
38.
Watari A, Takaki K, Higashiyama S, Li Y, Satomi Y, Takao T, Tanemura A, Yamaguchi Y, Katayama I, Shimakage M, Miyashiro I, Takami K, Kodama K, Yutsudo M: Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG. Oncogene. 2006, 25: 7373-7380. 10.1038/sj.onc.1209732.CrossRefPubMed
39.
Bahassi el M, Karyala S, Tomlinson CR, Sartor MA, Medvedovic M, Hennigan RF: Critical regulation of genes for tumor cell migration by AP-1. Clin Exp Metastasis. 2004, 21: 293-304. 10.1023/B:CLIN.0000046132.46946.dd.CrossRefPubMed
40.
De Corte V, Van Impe K, Bruyneel E, Boucherie C, Mareel M, Vandekerckhove J, Gettemans J: Increased importin-beta-dependent nuclear import of the actin modulating protein CapG promotes cell invasion. J Cell Sci. 2004, 117: 5283-5292. 10.1242/jcs.01410.CrossRefPubMed
41.
Van den Abbeele A, De Corte V, Van Impe K, Bruyneel E, Boucherie C, Bracke M, Vandekerckhove J, Gettemans J: Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett. 2007, 255: 57-70. 10.1016/j.canlet.2007.03.023.CrossRefPubMed
42.
Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A, Jenkins RE, Lemoine NR, Crnogorac-Jurcevic T, Yin HL, Costello E: Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut. 2007, 56: 95-106. 10.1136/gut.2005.083691.CrossRefPubMed
43.
Van Ginkel PR, Gee RL, Walker TM, Hu DN, Heizmann CW, Polans AS: The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim Biophys Acta. 1998, 1448: 290-297. 10.1016/S0167-4889(98)00133-5.CrossRefPubMed
44.
Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL, Riggins GJ: A public database for gene expression in human cancers. Cancer Res. 1999, 59: 5403-5407.PubMed
45.
Mithani SK, Mydlarz WK, Grumbine FL, Smith IM, Califano JA: Molecular genetics of premalignant oral lesions. Oral Dis. 2007, 13: 126-133. 10.1111/j.1601-0825.2006.01349.x.CrossRefPubMed
46.
Califano J, Westra WH, Meininger G, Corio R, Koch WM, Sidransky D: Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res. 2000, 6: 347-352.PubMed
Metadata
Title
Clinical significance of gelsolin-like actin-capping protein expression in oral carcinogenesis: an immunohistochemical study of premalignant and malignant lesions of the oral cavity
Authors
Hitomi Nomura
Katsuhiro Uzawa
Takashi Ishigami
Yukinao Kouzu
Hirofumi Koike
Katsunori Ogawara
Masashi Siiba
Hiroki Bukawa
Hidetaka Yokoe
Hitoshi Kubosawa
Hideki Tanzawa
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-39

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel

Research article

A prospective study of physical activity and the risk of pancreatic cancer among women (United States)

Research article

Analysis of the effects of exposure to acute hypoxia on oxidative lesions and tumour progression in a transgenic mouse breast cancer model

Research article

Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice

Research article

Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3

Research article

Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits